Grant: CIHR Fellowship
Université Laval
$96,250.00
A better understanding of the association between problem gambling and psychotic disorders in young adults: a new path towards recovery?
EF 2022-23
Résumé
Problem gambling (PBG) can lead to financial issues, social isolation and mental health problems, including suicide. Our previous study, the only one to date on this issue, suggests that young adults with psychotic disorders may be at increased risk of PBG and that the antipsychotic drug aripiprazole may contribute. However, no PBG screening tool or treatment have been adapted to this population, which this study will do while testing the following hypotheses:
1) Risk factors for PBG in individuals with FEP include substance abuse, impulsive personality disorder and aripiprazole use;
2) Current treatments for PBG, not adapted to this population, are insufficient to lead to recovery.
This study includes all adults (18-35 years) admitted between November 1st, 2019, and November 1st, 2023, to 2 first-episode psychosis clinics, which admit 200 individuals per year. We have developed an innovative screening procedure that assesses gambling habits, severity and the presence of a PBG diagnosis (DSM-5). This procedure has been used systematically in both clinics since November 1st, 2019. All study variables are collected from medical records at clinic admission and then every 6 months through May 1st, 2024. Survival analyses will determine PBG incidence and its risk factors. Interventions offered to individuals with PBG and their effectiveness will be documented. Around 800 people will be included, allowing the objectives to be met.
The results of this study will help to identify individuals most at risk for PBG and to offer them preventive measures, such as modification of antipsychotic treatment, if the link with aripiprazole use is confirmed. The screening procedure for PBG developed in this study will be deployed to all first-episode psychosis clinics of Quebec. This study is also part of a larger project (FRQ-SC grant) in which experts and patient partners will develop and test a treatment for PBG tailored to this population based on the results.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
473958
Name
Corbeil Olivier
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Clinical
Prcname2
Allied Health Professionals - Fellowships
Projecttitle
A better understanding of the association between problem gambling and psychotic disorders in young adults: a new path towards recovery?
Programtype2
Fellowship Programs
Orgnameinp2
Université Laval
Cihramount2
$96,250
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Behavioral Addiction; Comorbidity; Gambling Disorder; Mental Health; Multicentric Study; Problem Gambling; Prospective Cohort Study; Psychotic Disorder; Recovery; Schizophrenia
Abstract
Problem gambling (PBG) can lead to financial issues, social isolation and mental health problems, including suicide. Our previous study, the only one to date on this issue, suggests that young adults with psychotic disorders may be at increased risk of PBG and that the antipsychotic drug aripiprazole may contribute. However, no PBG screening tool or treatment have been adapted to this population, which this study will do while testing the following hypotheses:
1) Risk factors for PBG in individuals with FEP include substance abuse, impulsive personality disorder and aripiprazole use;
2) Current treatments for PBG, not adapted to this population, are insufficient to lead to recovery.
This study includes all adults (18-35 years) admitted between November 1st, 2019, and November 1st, 2023, to 2 first-episode psychosis clinics, which admit 200 individuals per year. We have developed an innovative screening procedure that assesses gambling habits, severity and the presence of a PBG diagnosis (DSM-5). This procedure has been used systematically in both clinics since November 1st, 2019. All study variables are collected from medical records at clinic admission and then every 6 months through May 1st, 2024. Survival analyses will determine PBG incidence and its risk factors. Interventions offered to individuals with PBG and their effectiveness will be documented. Around 800 people will be included, allowing the objectives to be met.
The results of this study will help to identify individuals most at risk for PBG and to offer them preventive measures, such as modification of antipsychotic treatment, if the link with aripiprazole use is confirmed. The screening procedure for PBG developed in this study will be deployed to all first-episode psychosis clinics of Quebec. This study is also part of a larger project (FRQ-SC grant) in which experts and patient partners will develop and test a treatment for PBG tailored to this population based on the results.
Competitiondate
202210
Approvedterm2
1 yr 9 mths
Pinamesdelim
Corbeil, Olivier
Approvedterm
1 an 9 mois
Cihrcontribution2
~ $96,250~ $0~